115 related articles for article (PubMed ID: 15799682)
1. Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs.
Chao SD; Maibach HI
Am J Clin Dermatol; 2005; 6(2):105-11. PubMed ID: 15799682
[TBL] [Abstract][Full Text] [Related]
2. Comparative assessment of four drug interaction compendia.
Vitry AI
Br J Clin Pharmacol; 2007 Jun; 63(6):709-14. PubMed ID: 17166171
[TBL] [Abstract][Full Text] [Related]
3. Concordance of severity ratings provided in four drug interaction compendia.
Abarca J; Malone DC; Armstrong EP; Grizzle AJ; Hansten PD; Van Bergen RC; Lipton RB
J Am Pharm Assoc (2003); 2004; 44(2):136-41. PubMed ID: 15098847
[TBL] [Abstract][Full Text] [Related]
4. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia.
Wong CM; Ko Y; Chan A
Ann Pharmacother; 2008 Dec; 42(12):1737-48. PubMed ID: 19033481
[TBL] [Abstract][Full Text] [Related]
5. Comparison of potentially hepatotoxic drugs among major US drug compendia.
Guo JJ; Wigle PR; Lammers K; Vu O
Res Social Adm Pharm; 2005 Sep; 1(3):460-79. PubMed ID: 17138490
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Clinical Compendia Used for Medicare Part D Coverage Determinations for Off-label Prescribing in Dermatology.
Barbieri JS; St Claire K; Mostaghimi A; Albrecht J
JAMA Dermatol; 2019 Mar; 155(3):315-320. PubMed ID: 30673082
[TBL] [Abstract][Full Text] [Related]
7. Compendia and anticancer therapy under Medicare.
Tillman K; Burton B; Jacques LB; Phurrough SE
Ann Intern Med; 2009 Mar; 150(5):348-50. PubMed ID: 19221368
[TBL] [Abstract][Full Text] [Related]
8. Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia.
Olvey EL; Clauschee S; Malone DC
Clin Pharmacol Ther; 2010 Jan; 87(1):48-51. PubMed ID: 19890252
[TBL] [Abstract][Full Text] [Related]
9. Systematic review: reliability of compendia methods for off-label oncology indications.
Abernethy AP; Raman G; Balk EM; Hammond JM; Orlando LA; Wheeler JL; Lau J; McCrory DC
Ann Intern Med; 2009 Mar; 150(5):336-43. PubMed ID: 19221366
[TBL] [Abstract][Full Text] [Related]
10. Commercial drug compendium information: a First World/Third World comparison.
Pleil AM; Pathak DS
Int J Health Serv; 1988; 18(4):587-602. PubMed ID: 3235245
[TBL] [Abstract][Full Text] [Related]
11. Poor concordance among drug compendia for proposed interactions between enzyme-inducing antiepileptic drugs and direct oral anticoagulants.
Acton EK; Willis AW; Gelfand MA; Kasner SE
Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1534-1538. PubMed ID: 31517414
[TBL] [Abstract][Full Text] [Related]
12. Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events.
Cohen JS
Arch Intern Med; 2001 Apr; 161(7):957-64. PubMed ID: 11295958
[TBL] [Abstract][Full Text] [Related]
13. A comparison of drug product information in four national compendia.
Alloza JL; Lasagna L
Clin Pharmacol Ther; 1983 Mar; 33(3):269-77. PubMed ID: 6825384
[TBL] [Abstract][Full Text] [Related]
14. Warfarin drug interactions: a comparative evaluation of the lists provided by five information sources.
Martins MA; Carlos PP; Ribeiro DD; Nobre VA; César CC; Rocha MO; Ribeiro AL
Eur J Clin Pharmacol; 2011 Dec; 67(12):1301-8. PubMed ID: 21701882
[TBL] [Abstract][Full Text] [Related]
15. Drug interactions involving antiepileptic drugs: assessment of the consistency among three drug compendia and FDA-approved labels.
Ekstein D; Tirosh M; Eyal Y; Eyal S
Epilepsy Behav; 2015 Mar; 44():218-24. PubMed ID: 25771206
[TBL] [Abstract][Full Text] [Related]
16. Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium.
Anthony M; Romero K; Malone DC; Hines LE; Higgins L; Woosley RL
Clin Pharmacol Ther; 2009 Oct; 86(4):425-9. PubMed ID: 19587643
[TBL] [Abstract][Full Text] [Related]
17. [Factors to consider in managing drug interactions in clinical practice].
Charpiat B; Allenet B; Roubille R; Escofier L; Bedouch P; Juste M; Rose FX; Conort O
Presse Med; 2008 Apr; 37(4 Pt 2):654-64. PubMed ID: 18035515
[TBL] [Abstract][Full Text] [Related]
18. Worldwide analysis of factors associated with medicines compendia publishing.
Arguello B; Fernandez-Llimos F
Int J Clin Pharm; 2013 Jun; 35(3):386-92. PubMed ID: 23536106
[TBL] [Abstract][Full Text] [Related]
19. Off-label cancer drug compendia found outdated and incomplete.
Mitka M
JAMA; 2009 Apr; 301(16):1645-6. PubMed ID: 19383947
[No Abstract] [Full Text] [Related]
20. Official USP Reference Standards: metrology concepts, overview, and scientific issues and opportunities.
Williams RL; ;
J Pharm Biomed Anal; 2006 Jan; 40(1):3-15. PubMed ID: 16303277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
